轻型新型冠状病毒肺炎患者临床特征分析

doi:10.3969/j.issn.2095-9400.2020.04.001

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (1447 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To analyze the epidemiology and clinical characteristics of patients with mild COVID-19. Methods: Retrospective analysis was performed on 11 patients with mild COVID-19 and 117 non-mild patients from multiple hospitals in Zhejiang Province from January 21 to March 6, 2020. The characteristics of epidemiology, demography, clinical manifestations and laboratory examinations were analyzed. Results: The median incubation period was 10(7-14) days in 11 patients with mild COVID-19 and 6(3-9) days in non-mild covid-19, showing significant difference (Z=-4.520, P<0.001). There were more female patients (8 cases) than male patients (3 cases) in the mild group, which was contrary to the non-mild group. The median age of mild group (28 years old) was lower than that of non-mild group (48 years old) (Z=-4.070, P<0.001). One patient had coexisting disease (9.1%) in mild group while there were 40 patients (34.2%) in non-mild group. Patients with fever were fewer in mild group than in non-mild group (36.4% vs. 73.5%, χ2=4.984, P=0.026). The proportion of patients with elevated CRP in mild group was lower than that in non-mild group (9.1% vs. 59.0%, χ2=8.184, P=0.004). The proportion of leukopenia patients in the two groups was similar. The proportion of mild patients receiving oxygen inhalation treatment and glucocorticoid treatment was lower than that of non-mild patients (36.4% vs. 96.7%, 0% vs. 6%, P<0.001). By March 6, 2020, 10 cases (90.9%) of mild patients had been cured and discharged, which was significantly higher than that of non-mild patients (18 cases, 15.4%, P<0.001). There was no death or aggravation in mild patients. The median course of the two groups was similar, but the median course of the female patients in the mild group was shorter than that of the male for 4 days. Conclusion: Mild COVID-19 patients showed imperceptible, long incubation period, mild symptoms, high CRP normal rate, normal CT, which may cause missed diagnosis and increased risk of virus transmission. Though mild patients had good prognosis, but they still need comprehensive treatment and close observation. In addition, there may be more mild patients and better prognosis in women than in men.

Key words： COVID-19 mild clinical characteristics

	Service
	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	DAI Wei
	LENG Zhefeng
	XU Xiaoting
	CHEN Xinmiao
	YU Wenwen
	LIN Hui
	FANG Wenxiong
	ZHENG Zhe
	ZHU Dan
	QIU Zhangwei
	YING Songmin
	DAI Yuanrong

URL:

https://xb.wmu.edu.cn/EN/10.3969/j.issn.2095-9400.2020.04.001 OR https://xb.wmu.edu.cn/EN/Y2020/V50/I4/259

[1] CHEN L, LIU W, ZHANG Q, et al. RNA based mNGS approach identifies a novel human coronavirus from two individual pneumonia cases in 2019 Wuhan outbreak[J]. Emerg Microbes Infect, 2020, 9(1): 313-319.
[2] HUANG C, WANG Y, LI X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China[J]. Lancet, 2020, 395(10223): 497-506.
[3] LU R, ZHAO X, LI J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding[J]. Lancet, 2020, 395(10224): 565-574.
[4] CHAN J F, YUAN S, KOK K H, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster[J]. Lancet, 2020, 395(10223): 514-523.
[5] CHEN N, ZHOU M, DONG X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study[J]. Lancet, 2020, 395(10223): 507-513.
[6] YANG X, YU Y, XU J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study[J]. Lancet Respir Med, 2020. DOI: 10.1016/S2213-2600 (20)30079-5.
[7] OTTER J A, DONSKEY C, YEZLI S, et al. Transmission of SARS and MERS coronaviruses and influenza virus in healthcare settings: the possible role of dry surface contami-nation[J]. J Hosp Infect, 2016, 92(3): 235-250.
[8] WU F, ZHAO S, YU B, et al. A new coronavirus associated with human respiratory disease in China[J]. Nature, 2020, 579(7798): 265-269.
[9] 中华人民共和国国家卫生健康委员会. 新型冠状病毒肺炎诊疗方案(试行第七版)[EB/OL]. (2020-03-03) [2020-03-17]. www.nhc.gov.cn/yzygj/s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989.shtml.
[10] XU X W, WU X X, JIANG X G, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series[J]. BMJ, 2020, 368: m606.
[11] GUAN W J, NI Z Y, HU Y, et al. Clinical characteristics of coronavirus disease 2019 in China[J]. N Engl J Med, 2020. DOI: 10.1056/NEJMoa2002032.
[12] WANG D, HU B, HU C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China[J]. JAMA, 2020. DOI: 10.1001/jama.2020.1585.
[13] LI Q, GUAN X, WU P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia[J]. N Engl J Med, 2020, 382(13): 1199-1207.
[14] ZOU L, RUAN F, HUANG M, et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients[J]. N Engl J Med, 2020, 382(12): 1177-1179.
[15] BAI Y, YAO L, WEI T, et al. Presumed asymptomatic carrier transmission of COVID-19[J]. JAMA, 2020, 323(14): 1406-1407.
[16] CAI J, XU J, LIN D, et al. A Case Series of children with 2019 novel coronavirus infection: clinical and epidemiological features[J]. Clin Infect Dis, 2020. DOI: 10.1093/cid/ciaa198.
[17] ZHOU F, YU T, DU R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study[J]. Lancet, 2020, 395(10229): 1054-1062.